Why LLY would drop partnership when: 1). "TT401 demonstrated HbA1c improvements of up to -1.43% (similar to the exenatide arm)". 2) Oral administering is is so much better/convenient than injection (with Exenatide). 3). There is a lawsuit going on with Exenatide.
Agree, TTHI is going to move back to $2 range once LLY confirm their partnership.